Ozempic and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ozempic (semaglutide) and Ibrance (palbociclib). Common drug interactions include fatigue among females and white blood cell count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Ozempic and Ibrance. It is created by eHealthMe based on reports of 65 people who take the same drugs from the FDA, and is updated regularly.

What is Ozempic?

Ozempic has active ingredients of semaglutide. It is often used in weight loss. eHealthMe is studying from 29,759 Ozempic users. Check the latest studies of Ozempic.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

On Jul, 02, 2026

65 people who take Ozempic and Ibrance together, and have interactions are studied.

What are the common drug interactions of Ozempic and Ibrance, by gender? *:

female:

Fatigue (feeling of tiredness)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Insomnia (sleeplessness)
Stomatitis (inflammation of mucous membrane of mouth)
Death
Neoplasm progression (growth of tumour)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Rash
Renal disorder (kidney disease)
Anal pruritus (anal itching)

male:

White blood cell count decreased

What are the common drug interactions of Ozempic and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Fatigue (feeling of tiredness)
Constipation
Insomnia (sleeplessness)
Night sweats (sweating in night)
White blood cell count decreased
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Glossodynia (a burning or painful sensation in the tongue)
Migraine (headache)
Oral pain
Seizure (abnormal excessive or synchronous neuronal activity in the brain)

50-59:

Hair disorder
Joint range of motion decreased (disease of joint movement)
Lymphadenopathy (disease or enlargement of lymph nodes)
Mobility decreased (ability to move is reduced)
Nausea (feeling of having an urge to vomit)
Neoplasm progression (growth of tumour)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pain in extremity
Red blood cell count decreased
Skin burning sensation

60+:

Fatigue (feeling of tiredness)
Diarrhoea
Death
Dizziness
Renal disorder (kidney disease)
Neoplasm progression (growth of tumour)
Anal pruritus (anal itching)
Blood glucose decreased
Tumour marker increased
Vomiting

What are the existing conditions these people have? *

Breast Cancer Female: 19 people, 29.23%
Breast Cancer Metastatic: 11 people, 16.92%
Breast Cancer: 5 people, 7.69%
Weight Decreased: 4 people, 6.15%

* Approximation only. Some reports may have incomplete information.

Do you take Ozempic and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously